Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Current Leases (2023 - 2025)

Historic Current Leases for Maravai Lifesciences Holdings (MRVI) over the last 3 years, with Q2 2025 value amounting to $876000.0.

  • Maravai Lifesciences Holdings' Current Leases rose 2338.03% to $876000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $876000.0, marking a year-over-year increase of 2338.03%. This contributed to the annual value of $792000.0 for FY2024, which is 2511.85% up from last year.
  • Maravai Lifesciences Holdings' Current Leases amounted to $876000.0 in Q2 2025, which was up 2338.03% from $834000.0 recorded in Q1 2025.
  • Over the past 5 years, Maravai Lifesciences Holdings' Current Leases peaked at $876000.0 during Q2 2025, and registered a low of $300000.0 during Q1 2023.
  • Its 3-year average for Current Leases is $672300.0, with a median of $691000.0 in 2024.
  • In the last 5 years, Maravai Lifesciences Holdings' Current Leases skyrocketed by 12400.0% in 2024 and then skyrocketed by 2338.03% in 2025.
  • Quarter analysis of 3 years shows Maravai Lifesciences Holdings' Current Leases stood at $633000.0 in 2023, then rose by 25.12% to $792000.0 in 2024, then increased by 10.61% to $876000.0 in 2025.
  • Its Current Leases was $876000.0 in Q2 2025, compared to $834000.0 in Q1 2025 and $792000.0 in Q4 2024.